Research Overview
Palmitoylethanolamide (PEA) is an endogenous fatty-acid amide that has been investigated primarily for its analgesic and anti-inflammatory potential, with most clinical research focusing on pain conditions (often described as neuropathic, inflammatory, or mixed pain). The study adds to this pain-focused literature by evaluating acute menstrual pain in a randomized, double-blind, placebo-controlled crossover design. In that study, a single 300 mg dose taken at pain onset (with an optional second dose after 2 hours) produced statistically significant reductions in numerical pain rating scale scores versus placebo at several post-dose time points (1 to 2.5 hours), while showing no apparent differences in treatment satisfaction, rescue medication use, or adverse events over the short observation window.
The strongest evidence from the study supports PEA as a well-tolerated option that can reduce pain intensity compared with placebo in the acute setting of menstrual pain, at least within the first few hours after dosing. The trial’s randomized, double-blind, placebo-controlled crossover methodology strengthens causal inference for short-term analgesic efficacy and supports a favorable short-term safety profile at the studied dose. However, the evidence summarized here is specific to acute pain reduction over hours and does not establish longer-term benefits, comparative effectiveness versus standard analgesics, or effects on broader functional outcomes.
Key areas needing more research include replication in larger and more diverse populations; evaluation across multiple menstrual cycles to assess consistency of effect; dose–response studies and optimization of timing (e.g., pre-emptive vs onset dosing); and head-to-head comparisons with standard treatments (e.g., NSAIDs) using clinically meaningful endpoints such as functional impairment, quality of life, and reduction in rescue medication. Additional work is also needed to characterize longer-term safety with repeated use, identify subgroups most likely to benefit, and clarify mechanisms and biomarkers that correlate with response.
1. What conditions has Palmitoylethanolamide been studied for?
Acute menstrual pain (dysmenorrhea): Studied in a randomized, double-blind, placebo-controlled crossover trial in adults, using PEA at the onset of menstrual pain.
Pain more broadly (general): The study states PEA is “effective in reducing pain,” but the only specific condition described in the study is menstrual pain.
2. Does it work in treating those conditions? Summarize the evidence.
-
Menstrual pain: Yes, in the provided study PEA reduced pain versus placebo at multiple time points after dosing.
Design: Randomized, double-blind, placebo-controlled crossover study (Australia; May–Dec 2023) in adults >18.
Dose: 300 mg PEA at pain onset; a second dose allowed after 2 hours if pain persisted.
Outcome: Numerical Pain Rating Scale (NRS) measured every 30 minutes up to 4 hours.
-
Findings: Statistically significant pain reductions compared with placebo at:
1 hour (p = .045)
1.5 hours (p = .009)
2 hours (p = .015)
2.5 hours (p = .039)
Other outcomes: No differences vs placebo in treatment satisfaction, rescue medication use, or adverse events.
Limitations (based on what is provided): The study does not report sample size, effect sizes (e.g., mean NRS change), or longer-term outcomes across cycles, which limits conclusions about magnitude of benefit and durability.
3. What health benefits does it have?
Short-term reduction of acute menstrual pain after dosing, with significant improvements observed between 1 and 2.5 hours post-dose compared with placebo (per the trial described).
Potential analgesic benefit more generally is suggested by the study’s statement that PEA is effective in reducing pain, but specific additional indications are not detailed in the provided text.
4. Does it have any downsides or side effects?
Adverse events: In the menstrual pain trial, there was no difference in adverse events between PEA and placebo.
Tolerability: The study describes PEA as well-tolerated.
Practical downside/uncertainty: The study did not show differences in treatment satisfaction or rescue medication use, and the study does not provide detailed safety data (types of adverse events, lab measures, or rare events), so uncommon side effects cannot be assessed from this study alone.
5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?
The study does not report any pharmacogenomic analyses or genotype-stratified outcomes for PEA. Therefore:
No specific genetic variants can be identified from this evidence as predicting better response, worse response, or increased risk of side effects.
Clinical implication: Based on the study alone, there is insufficient evidence to recommend PEA differently for any particular genetic subgroup.
References
-
Palmitoylethanolamide (Levagen+) for acute menstrual pain: a randomized, crossover, double-blind, placebo-controlled trial
Amanda Rao, Jane Erickson, David Briskey (2025)
This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!